Health Economics›Chimeric antigen receptor T cells›Low-dose conditioning regimens for cellular therapy, all lines of therapy

Low-dose conditioning regimens for cellular therapy, all lines of therapy

Chimeric antigen receptor T cells · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cyclophosphamide and Fludarabine (FC) Variant #15	—	R 14 005	—	~20.6 mo	~37.0 mo	~8	~R 112 036 PFS proxy · indirect	4
Bendamustine monotherapy Variant #01	—	R 7 084	—	~16.5 mo	—	~8	~R 56 672 PFS proxy · indirect	2
Cytarabine and Etoposide (CYVE) Variant #06	—	R 4 351	—	—	~9.2 mo	~2	~R 8 701 PFS proxy · indirect	—

3 of 3 regimens shown